Literature DB >> 11951147

Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: susceptibility to psychotic states and implications for relapse of schizophrenia.

K Yui1, S Ikemoto, K Goto, K Nishijima, T Yoshino, T Ishiguro.   

Abstract

In this study, we examined the relationship between increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic changes, and susceptibility to subsequent spontaneous recurrences of methamphetamine (MAP) psychosis (i.e., flashbacks). The subjects were 81 physically healthy females. Plasma monoamine metabolite levels were assayed in: 19 flashbackers, of whom 11 experienced a single flashback and 8 exhibited subsequent flashbacks; 20 non-flashbackers with a history of MAP psychosis; 8 subjects with persistent MAP psychosis; and 23 MAP users and 11 non-user controls. All 19 flashbackers had undergone frightening and stressful experiences during previous MAP use. Mild psychosocial stressors then triggered their flashbacks. During flashbacks, plasma norepinephrine levels increased, with a small increase in plasma levels of 3-methoxytyramine, which is an index of dopamine release. Among the 19 flashbackers, the 8 with subsequent episodes had increased NE levels and slightly increased 3-methoxytyramine levels, while the 11 with a single episode displayed small increases in norepinephrine and 3-methoxytyramine levels. Thus, noradrenergic hyperactivity and increased dopamine release in response to mild psychosocial stressors may be responsible for the development of flashbacks. Robust noradrenergic hyperactivity with slightly increased DA release in response to mild stress may induce susceptibility to subsequent flashbacks. Flashbacks and schizophrenia may share the pathophysiology of susceptibility to recurrence of paranoid-hallucinatory states such as stress sensitization, and also noradrenergic hyperactivity and enhanced DA release. Thus, flashbacks may provide an appropriate model of susceptibility to paranoid-hallucinatory states of schizophrenia. The model psychosis is a potential tool for validating basic neurobiological concepts thought to be related to the schizophrenia. A better understanding of the neurobiological mechanisms of susceptibility to recurrence could provide useful information in the development of strategies for preventing relapse.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11951147     DOI: 10.1055/s-2002-25067

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  7 in total

1.  A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia.

Authors:  Kathryn M Gill; Daniel J Lodge; James M Cook; Shamim Aras; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2011-05-11       Impact factor: 7.853

2.  Repeated methamphetamine treatment impairs spatial working memory in rats: reversal by clozapine but not haloperidol.

Authors:  Taku Nagai; Kazuhiro Takuma; Misato Dohniwa; Daisuke Ibi; Hiroyuki Mizoguchi; Hiroyuki Kamei; Toshitaka Nabeshima; Kiyofumi Yamada
Journal:  Psychopharmacology (Berl)       Date:  2007-05-20       Impact factor: 4.530

3.  Presynaptic regulation of dopamine transmission in schizophrenia.

Authors:  Gholson J Lyon; Anissa Abi-Dargham; Holly Moore; Jeffrey A Lieberman; Jonathan A Javitch; David Sulzer
Journal:  Schizophr Bull       Date:  2009-06-12       Impact factor: 9.306

4.  Khat use as risk factor for psychotic disorders: a cross-sectional and case-control study in Somalia.

Authors:  Michael Odenwald; Frank Neuner; Maggie Schauer; Thomas Elbert; Claudia Catani; Birke Lingenfelder; Harald Hinkel; Heinz Häfner; Brigitte Rockstroh
Journal:  BMC Med       Date:  2005-02-12       Impact factor: 8.775

5.  Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients.

Authors:  Homa Zarrabi; Mohammadrasoul Khalkhali; Azam Hamidi; Reza Ahmadi; Maryam Zavarmousavi
Journal:  BMC Psychiatry       Date:  2016-02-25       Impact factor: 3.630

Review 6.  mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders.

Authors:  Larisa Ryskalin; Fiona Limanaqi; Alessandro Frati; Carla L Busceti; Francesco Fornai
Journal:  Int J Mol Sci       Date:  2018-07-30       Impact factor: 5.923

Review 7.  Influence of Prenatal Methamphetamine Abuse on the Brain.

Authors:  Anežka Tomášková; Romana Šlamberová; Marie Černá
Journal:  Epigenomes       Date:  2020-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.